A new drug cuts the risk of death from melanoma by 30 percent, according to a late-stage clinical trial of the Bristol-Myers Squibb medicine, ipilimumab. Melanoma is an aggressive skin cancer, which rapidly spreads to organs, and the survival time after it metastasizes is usually six to nine months. Few treatments exist. In the study of 676 patients, more than 20 percent of those who took ipilimumab were alive after two years, with some alive after four. The dose was a 90-minute infusion every three weeks, for a total of four doses. The drug helps the immune system’s T-cells fight the cancer.
Unlock a year of full access to The Daily Beast for $35.
Monthly
$1
First monththen $5.99/month
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $5.99 monthly. Cancel anytime
Annual
$35
First yearthen $59.99/year
Discounted annual rate - Save 47%
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $59.99 yearly. Cancel anytime
Best Value
Premium
$79
First yearthen $119.99/year
Discounted annual rate
Full access to the Daily Beast Substack ($60 value)*
Premium ad-free reading
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $119.99 yearly. Cancel anytime
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Looks like you already have a subscription!
You're all set!
Thanks for subscribing.
Subscription$0.00
Total$0.00
OR
Loading subscription options
Register below to read this article for free or subscribe to unlock unlimited access to The Daily Beast.
Monthly
$1
First monththen $5.99/month
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $5.99 monthly. Cancel anytime
Annual
$35
First yearthen $59.99/year
Discounted annual rate - Save 47%
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $59.99 yearly. Cancel anytime
Best Value
Premium
$79
First yearthen $119.99/year
Discounted annual rate
Full access to the Daily Beast Substack ($60 value)*
Premium ad-free reading
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $119.99 yearly. Cancel anytime
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.